Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimal management of hormone receptor positive metastatic breast cancer in 2016

(2015) Tomas Reinert et al.   Therapeutic Advances in Medical Oncology

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

(2014) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer

(2012) Julia A Beaver et al.   Future Oncology

Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality

(2011) Montserrat Vera-Llonch et al.   BMC CANCER

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer

(2010) Maureen J. Lage et al.   JOURNAL OF MEDICAL ECONOMICS